Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPTLC1 | O15269 | 1/20 | 0.40 |
| ▸ | SPTLC2 | O15270 | 1/20 | 0.40 |
| ▸ | LNPEP | Q9UIQ6 | 3/20 | 0.32 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.31 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.30 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14259723 | 0.77 | LNPEP (0.33) | SPTLC1SPTLC2LNPEP | |
| SCHEMBL14145145 | 0.73 | SPTLC1 (0.41) | SPTLC1SPTLC2LNPEPS1PR4S1PR1 | |
| SCHEMBL14144988 | 0.72 | SPTLC1 (0.43) | SPTLC1SPTLC2CSNK1ES1PR4S1PR1 | |
| SCHEMBL14144991 | 0.69 | SPTLC1 (0.42) | SPTLC1SPTLC2 | |
| SCHEMBL14145262 | 0.68 | BRS3 (0.43) | SPTLC1SPTLC2LNPEPS1PR4S1PR1 | |
| SCHEMBL14145247 | 0.68 | GPR84 (0.50) | SPTLC1SPTLC2 | |
| SCHEMBL14145146 | 0.65 | SPTLC1 (0.40) | SPTLC1SPTLC2 | |
| SCHEMBL21755168 | 0.65 | OPRM1 (0.38) | — | |
| SCHEMBL14169310 | 0.65 | RARB (0.44) | LNPEPCSNK1ES1PR4S1PR1S1PR5 | |
| SCHEMBL19231989 | 0.63 | GPR84 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008083280-A1 | COMPOUNDS AND METHODS OF TREATING INSULIN RESISTANCE AND CARDIOMYOPATHY | TRANSITION THERAPEUTICS INC. (CA) | 2008-07-10 | — | — | WO | disclosed |